{"id":"https://openalex.org/W2811086367","doi":"https://doi.org/10.1177/1078155218785002","title":"Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?","display_name":"Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?","publication_year":2018,"publication_date":"2018-06-22","ids":{"openalex":"https://openalex.org/W2811086367","doi":"https://doi.org/10.1177/1078155218785002","mag":"2811086367","pmid":"https://pubmed.ncbi.nlm.nih.gov/29933728"},"language":"en","primary_location":{"id":"doi:10.1177/1078155218785002","doi":"https://doi.org/10.1177/1078155218785002","is_oa":false,"landing_page_url":"https://doi.org/10.1177/1078155218785002","pdf_url":null,"source":{"id":"https://openalex.org/S66425452","display_name":"Journal of Oncology Pharmacy Practice","issn_l":"1078-1552","issn":["1078-1552","1477-092X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Oncology Pharmacy Practice","raw_type":"journal-article"},"volume":null,"type":"editorial","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://ibn.idsi.md/vizualizare_articol/127769","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001190634","display_name":"Constantin A Dasanu","orcid":"https://orcid.org/0000-0003-0425-8394","observed_orcids":["https://orcid.org/0000-0003-0425-8394"]},"institutions":[{"id":"https://openalex.org/I1327543694","display_name":"Eisenhower Medical Center","ror":"https://ror.org/050wjeh45","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1327543694"]},{"id":"https://openalex.org/I2800935791","display_name":"UC San Diego Health System","ror":"https://ror.org/01kbfgm16","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Constantin A Dasanu","raw_affiliation_strings":["Lucy Curci Cancer Center, Eisenhower Medical Center, Rancho Mirage, USA","University of California San Diego Health System, San Diego, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lucy Curci Cancer Center, Eisenhower Medical Center, Rancho Mirage, USA","institution_ids":["https://openalex.org/I1327543694"]},{"raw_affiliation_string":"University of California San Diego Health System, San Diego, USA","institution_ids":["https://openalex.org/I2800935791","https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040779920","display_name":"Michael Del Rosario","orcid":"https://orcid.org/0000-0003-4298-5509","observed_orcids":["https://orcid.org/0000-0003-4298-5509"]},"institutions":[{"id":"https://openalex.org/I1327543694","display_name":"Eisenhower Medical Center","ror":"https://ror.org/050wjeh45","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1327543694"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Del Rosario","raw_affiliation_strings":["Department of Medicine, Eisenhower Medical Center, Rancho Mirage, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Eisenhower Medical Center, Rancho Mirage, USA","institution_ids":["https://openalex.org/I1327543694"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001653809","display_name":"Ion Codreanu","orcid":"https://orcid.org/0000-0002-2644-5572","observed_orcids":["https://orcid.org/0000-0002-2644-5572"]},"institutions":[{"id":"https://openalex.org/I4210124354","display_name":"Nicolae Testemi\u021banu State University of Medicine and Pharmacy","ror":"https://ror.org/03xww6m08","country_code":"MD","type":"education","lineage":["https://openalex.org/I4210124354"]}],"countries":["MD"],"is_corresponding":false,"raw_author_name":"Ion Codreanu","raw_affiliation_strings":["Department of Radiology and Imaging, State University of Medicine and Pharmacy \u201cNicolae Testemitanu\u201d, Chisinau, Moldova"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiology and Imaging, State University of Medicine and Pharmacy \u201cNicolae Testemitanu\u201d, Chisinau, Moldova","institution_ids":["https://openalex.org/I4210124354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069340173","display_name":"David M. Hyams","orcid":"https://orcid.org/0000-0002-5680-9488","observed_orcids":["https://orcid.org/0000-0002-5680-9488"]},"institutions":[{"id":"https://openalex.org/I1327543694","display_name":"Eisenhower Medical Center","ror":"https://ror.org/050wjeh45","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1327543694"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M Hyams","raw_affiliation_strings":["Department of Surgical Oncology, Eisenhower Medical Center, Rancho Mirage, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Surgical Oncology, Eisenhower Medical Center, Rancho Mirage, USA","institution_ids":["https://openalex.org/I1327543694"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047155663","display_name":"Steven Charles Plaxe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327543694","display_name":"Eisenhower Medical Center","ror":"https://ror.org/050wjeh45","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1327543694"]},{"id":"https://openalex.org/I2800935791","display_name":"UC San Diego Health System","ror":"https://ror.org/01kbfgm16","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven C Plaxe","raw_affiliation_strings":["Lucy Curci Cancer Center, Eisenhower Medical Center, Rancho Mirage, USA","University of California San Diego Health System, San Diego, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lucy Curci Cancer Center, Eisenhower Medical Center, Rancho Mirage, USA","institution_ids":["https://openalex.org/I1327543694"]},{"raw_affiliation_string":"University of California San Diego Health System, San Diego, USA","institution_ids":["https://openalex.org/I2800935791","https://openalex.org/I36258959"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5001190634"],"corresponding_institution_ids":["https://openalex.org/I1327543694","https://openalex.org/I2800935791","https://openalex.org/I36258959"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"25","issue":"1","first_page":"214","last_page":"216"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/merkel-cell-carcinoma","display_name":"Merkel cell carcinoma","score":1.0},{"id":"https://openalex.org/keywords/immunocompromised-patients","display_name":"immunocompromised patients","score":0.9750000238418579},{"id":"https://openalex.org/keywords/pd-1-pd-l1-inhibitors","display_name":"PD-1/PD-L1 inhibitors","score":0.9580000042915344},{"id":"https://openalex.org/keywords/avelumab","display_name":"avelumab","score":0.9800000190734863},{"id":"https://openalex.org/keywords/immunosenescence","display_name":"immunosenescence","score":0.9369999766349792},{"id":"https://openalex.org/keywords/lymphopenia","display_name":"lymphopenia","score":0.9890000224113464},{"id":"https://openalex.org/keywords/disease-stage","display_name":"disease stage","score":0.781000018119812},{"id":"https://openalex.org/keywords/survival-outcomes","display_name":"survival outcomes","score":0.6890000104904175},{"id":"https://openalex.org/keywords/mortality","display_name":"mortality","score":0.33500000834465027},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.5220000147819519}],"concepts":[{"id":"https://openalex.org/C2778342957","wikidata":"https://www.wikidata.org/wiki/Q1711744","display_name":"Merkel cell carcinoma","level":3,"score":0.9910394549369812},{"id":"https://openalex.org/C2777381376","wikidata":"https://www.wikidata.org/wiki/Q21083261","display_name":"Avelumab","level":5,"score":0.8596491813659668},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.829947829246521},{"id":"https://openalex.org/C2780291066","wikidata":"https://www.wikidata.org/wiki/Q1570264","display_name":"Merkel cell","level":4,"score":0.7266313433647156},{"id":"https://openalex.org/C2776187983","wikidata":"https://www.wikidata.org/wiki/Q1921796","display_name":"Merkel cell polyomavirus","level":4,"score":0.5816041231155396},{"id":"https://openalex.org/C2777789703","wikidata":"https://www.wikidata.org/wiki/Q192102","display_name":"Skin cancer","level":3,"score":0.5021612644195557},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.4728268086910248},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4302583932876587},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4152359664440155},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3620074391365051},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.3396049737930298},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.3344092071056366},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.309878408908844}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001379","descriptor_name":"Azathioprine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001379","descriptor_name":"Azathioprine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015266","descriptor_name":"Carcinoma, Merkel Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015266","descriptor_name":"Carcinoma, Merkel Cell","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D016867","descriptor_name":"Immunocompromised Host","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016867","descriptor_name":"Immunocompromised Host","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1177/1078155218785002","doi":"https://doi.org/10.1177/1078155218785002","is_oa":false,"landing_page_url":"https://doi.org/10.1177/1078155218785002","pdf_url":null,"source":{"id":"https://openalex.org/S66425452","display_name":"Journal of Oncology Pharmacy Practice","issn_l":"1078-1552","issn":["1078-1552","1477-092X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Oncology Pharmacy Practice","raw_type":"journal-article"},{"id":"pmid:29933728","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29933728","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners","raw_type":"Journal Article"},{"id":"pmh:oai:ibn.idsi.md:127769","doi":null,"is_oa":true,"landing_page_url":"https://ibn.idsi.md/vizualizare_articol/127769","pdf_url":null,"source":null,"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Oncology Pharmacy Practice 25 (1) 214-216","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:ibn.idsi.md:127769","doi":null,"is_oa":true,"landing_page_url":"https://ibn.idsi.md/vizualizare_articol/127769","pdf_url":null,"source":null,"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Oncology Pharmacy Practice 25 (1) 214-216","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":7,"referenced_works":["https://openalex.org/W2119837814","https://openalex.org/W2513660003","https://openalex.org/W2766831098","https://openalex.org/W2773578465","https://openalex.org/W2792936868","https://openalex.org/W2796433994","https://openalex.org/W2891150015"],"related_works":["https://openalex.org/W2891150015","https://openalex.org/W2917300337","https://openalex.org/W7221339212","https://openalex.org/W3032886642","https://openalex.org/W4409143475","https://openalex.org/W4366177915","https://openalex.org/W2920983234","https://openalex.org/W4412863751","https://openalex.org/W3046583279","https://openalex.org/W2763258520"],"abstract_inverted_index":{"Cases":[0],"of":[1,54,91,113],"Merkel":[2,31,56,94,114,125],"cell":[3,32,57,95,115,126],"carcinoma":[4,33,58,96,127],"have":[5],"become":[6],"increasingly":[7],"more":[8,46,66],"common":[9],"in":[10,27,35,48,78,85,103,110,123],"the":[11,29,111],"last":[12],"two":[13],"decades,":[14],"and":[15,39,64,88],"its":[16],"incidence":[17],"has":[18],"been":[19],"predicted":[20],"to":[21,76],"climb":[22],"further.":[23],"Immunosenescence":[24],"might":[25,43],"explain":[26],"part":[28],"higher":[30],"prevalence":[34],"seniors":[36],"aged":[37],"70":[38],"older.":[40],"This":[41],"cancer":[42],"also":[44],"be":[45],"aggressive":[47],"immunocompromised":[49,55,124],"patients.":[50],"In":[51],"a":[52,65],"subset":[53],"patients,":[59],"we":[60],"identified":[61],"significant":[62],"lymphopenia":[63],"advanced":[67],"disease":[68],"stage":[69],"compared":[70],"with":[71,131],"their":[72,89],"immunocompetent":[73,86],"counterparts.":[74],"Time":[75],"death":[77,92],"this":[79],"cohort":[80],"was":[81,97],"much":[82],"shorter":[83],"than":[84],"subjects,":[87],"likelihood":[90],"from":[93],"five":[98],"times":[99],"higher.":[100],"Avelumab":[101],"approval":[102],"2017":[104],"represents":[105],"an":[106],"important":[107],"step":[108],"forward":[109],"therapy":[112],"carcinoma.":[116],"Hopefully,":[117],"PD1/PDL1":[118],"inhibitors":[119],"will":[120],"improve":[121],"survival":[122],"hosts,":[128],"traditionally":[129],"linked":[130],"inferior":[132],"clinical":[133],"outcomes.":[134]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-07-10T00:00:00"}